Immunocore, headquartered in Abingdon, Oxfordshire, United Kingdom, is a privately owned, clinical-stage, biotechnology company discovering and developing highly innovative biotherapeutics known as ImmTACs for the treatment of cancer and a range of other serious diseases. Its world-leading proprietary T Cell Receptor (TCR) technology exploits the power of the body’s own immune system to find and kill diseased cells.
Founded in 2008, Immunocore traces its roots to Avidex, which was founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and Chief Scientific Officer, Dr Bent Jakobsen. Immunocore has very experienced management and a highly qualified scientific team that have successfully developed immunotherapies for the treatment of serious diseases including cancer.
Immunocore has established a robust technology platform which has yielded an ImmTAC clinical candidate, IMCgp100, currently in Phase I/II clinical trials in melanoma patients in both the US and UK.
Immunocore has a robust ImmTAC technology platform allowing for the generation of Good Manufacturing Practice (GMP) compliant, fully scalable manufacturing processes. The Company has established regulatory pathways approved by the Food and Drug Administration (FDA) and Medicines and Healthcare products Regulatory Agency (MHRA) that will form the basis for development of future ImmTAC programmes.